CoChat
Sign Up
Cited by 75

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Are NSAIDs useful to treat Alzheimer’s disease or mild cognitive impairment

Imbimbo·2010·Frontiers in Aging Neuroscience
DOI 10.3389/fnagi.2010.00019PMC PMC2912027
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fnagi.2010.00019

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Lack of robust efficacy in trials targeting amyloid and inflammatory pathways suggests that other mechanisms are at play.

    “The lack of robust efficacy in trials that utilize therapies directed against amyloid and inflammatory pathways, even when initiated relatively early in the disease (Selkoe, 2019; Imbimbo et al., 2010), suggests that other mechanisms are at play.”

    From Inhibiting USP16 rescues stem cell aging and memory in an Alzheimer’s model (2022) · cites this paper as Imbimbo et al., 2010

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 83

  1. Aisen P. S. Davis K. L. (1994). Inflammatory mechanisms in Alzheimer's disease. Implications for therapy. Am. J. Psychiatr. 151, 1105– 1113 7518651
  2. Aisen P. S. Davis K. L. Berg J. D. Schafer K. Campbell K. Thomas R. G. Weiner M. F. Farlow M. R. Sano M. Grundman M. Thal L. J. (2000). A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's Disease Cooperative Study. Neurology 54, 588– 593 10680787
  3. Aisen P. S. Schafer K. A. Grundman M. Pfeiffer E. Sano M. Davis K. L. Farlow M. R. Jin S. Thomas R. G. Thal L. J. (2003). Effects of rofecoxib or naproxen vs. placebo on Alzheimer disease progression. JAMA 289, 2819– 2826 10.1001/jama.289.21.2819 12783912 · DOI · Paper page
  4. Aisen P. S. Schmeidler J. Pasinetti G. M. (2002). Randomized pilot study of nimesulide treatment in Alzheimer's disease. Neurology 58, 1050– 1054 11940691
  5. Alafuzoff I. Overmyer M. Helisalmi S. Soininen H. (2000). Lower counts of astroglia and activated microglia in patients with Alzheimer's disease with regular use of non-steroidal anti-inflammatory drugs. J. Alzheimers Dis. 2, 37– 46 12214109
  6. Arvanitakis Z. Grodstein F. Bienias J. L. Schneider J. A. Wilson R. S. Kelly J. F. Evans D. A. Bennett D. A. (2008). Relation of NSAIDs to incident AD, change in cognitive function, and AD pathology. Neurology 70, 2219– 2225 10.1212/01.wnl.0000313813.48505.86 18519870 · DOI
  7. Avramovich Y. Amit T. Youdim M. B. (2002). Non-steroidal anti-inflammatory drugs stimulate secretion of non-amyloidogenic precursor protein. J. Biol. Chem. 277, 31466– 31473 10.1074/jbc.M201308200 12070143 · DOI
  8. Backsai B. J. Kajdasz S. T. Christie R. H. Carter C. Games D. Seubert P. Schenk D. Hyman B. T. (2001). Imaging of amyloid-b deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy. Nat. Med. 7, 369– 372 10.1038/85525 11231639 · DOI
  9. Blasko I. Veerhuis R. Stampfer-Kountchev M. Saurwein-Teissl M. Eikelenboom P. Grubeck-Loebenstein B. (2000). Costimulatory effects of interferon-γ and interleukin-1β or tumor necrosis factor α on the synthesis of Aβ1-40 and Aβ1-42 by human astrocytes. Neurobiol. Dis. 7, 682– 689 10.1006/nbdi.2000.0321 11114266 · DOI · Paper page
  10. Bolmont T. Haiss F. Eicke D. Radde R. Mathis C. A. Klunk W. E. Kohsaka S. Jucker M. Calhoun M. E. (2008). Dynamics of the microglial/amyloid interaction indicate a role in plaque maintenance. J. Neurosci. 28, 4283– 4292 10.1523/JNEUROSCI.4814-07.2008 18417708 PMC3844768 · DOI · Paper page
  11. Breitner J. C. Haneuse S. J. Walker R. Dublin S. Crane P. K. Gray S. L. Larson E. B. (2009). Risk of dementia and AD with prior exposure to NSAIDs in an elderly community-based cohort. Neurology 72, 1899– 1905 10.1212/WNL.0b013e3181a18691 19386997 PMC2690966 · DOI
  12. Cacci E. Ajmone-Cat M. A. Anelli T. Biagioni S. Minghetti L. (2008). In vitro neuronal and glial differentiation from embryonic or adult neural precursor cells are differently affected by chronic or acute activation of microglia. Glia 56, 412– 425 10.1002/glia.20616 18186084 · DOI
  13. Carulla N. Caddy G. L. Hall D. R. Zurdo J. Gairí M. Feliz M. Giralt E. Robinson C. V. Dobson C. M. (2005). Molecular recycling within amyloid fibrils. Nature 436, 554– 558 10.1038/nature03986 16049488 · DOI
  14. Casper D. Yaparpalvi U. Rempel N. Werner P. (2000). Ibuprofen protects dopaminergic neurons against glutamate toxicity in vitro. Neurosci. Lett. 289, 201– 204 10.1016/S0304-3940(00)01294-5 10961664 · DOI
  15. Cornelius C. Fastbom J. Winblad B. Viitanen M. (2004). Aspirin, NSAIDs, risk of dementia, and influence of the apolipoprotein E ε4 allele in an elderly population. Neuroepidemiology 23, 135– 143 10.1159/000075957 15084783 · DOI
  16. Couzin J. (2004). Clinical trials. Nail-biting time for trials of COX-2 drugs. Science 306, 1673– 1675 10.1126/science.306.5702.1673 15576585 · DOI
  17. de Craen A. J. Gussekloo J. Vrijsen B. Westendorp R. G. (2005). Meta-analysis of nonsteroidal antiinflammatory drug use and risk of dementia. Am. J. Epidemiol. 161, 114– 120 10.1093/aje/kwi029 15632261 · DOI
  18. de Jong D. Jansen R. Hoefnagels W. Jellesma-Eggenkamp M. Verbeek M. Borm G. Kremer B. (2008). No effect of one-year treatment with indomethacin on Alzheimer's disease progression: a randomized controlled trial. PLoS ONE 3, e1475 10.1371/journal.pone.0001475 18213383 PMC2194921 · DOI
  19. Dill J. Patel A. R. Yang X. L. Bachoo R. Powell C. M. Li S. (2010). A molecular mechanism for ibuprofen-mediated RhoA inhibition in neurons. J. Neurosci. 30, 963– 972 10.1523/JNEUROSCI.5045-09.2010 20089905 PMC3904382 · DOI
  20. Doody R. S. (2008). Cholinesterase inhibitors and memantine: best practices. CNS Spectr. 13(10 Suppl. 16), 34– 35 18955960
  21. Ekdahl C. T. Kokaia Z. Lindvall O. (2009). Brain inflammation and adult neurogenesis: the dual role of microglia. Neuroscience 158, 1021– 1029 10.1016/j.neuroscience.2008.06.052 18662748 · DOI · Paper page
  22. Etminan M. Gill S. Samii A. (2003). Effect of non-steroidal antiinflammatory drugs on risk of Alzheimer's disease: systematic review and meta-analysis of observational studies. BMJ 327, 128– 132 10.1136/bmj.327.7407.128 12869452 PMC165707 · DOI · Paper page
  23. Finckh A. Aronson M. D. (2005). Cardiovascular risks of cyclooxygenase-2 inhibitors: where we stand now. Ann. Intern. Med. 142, 212– 214 15684210
  24. Fitzgerald G. A. (2004). Coxibs and cardiovascular disease. N. Engl. J. Med. 351, 1709– 1711 10.1056/NEJMp048288 15470192 · DOI
  25. Fu Q. Hue J. Li S. (2007). Nonsteroidal anti-inflammatory drugs promote axon regeneration via RhoA inhibition. J. Neurosci. 27, 4154– 4164 10.1523/JNEUROSCI.4353-06.2007 17428993 PMC6672522 · DOI
  26. Fuller S. Steele M. Münch G. (2009). Activated astroglia during chronic inflammation in Alzheimer's disease-Do they neglect their neurosupportive roles? Mutat. Res. [Epub ahead of print]. 19748514
  27. Gómez-Isla T. Blesa R. Boada M. Clarimón J. Del Ser T. Domenech G. Ferro J. M. Gómez-Ansón B. Manubens J. M. Martínez-Lage J. M. Muñoz D. Peña-Casanova J. Torres F. (2008). TRIMCI Study Group. A randomized, double-blind, placebo controlled-trial of triflusal in mild cognitive impairment: the TRIMCI study. Alzheimer Dis. Assoc. Disord. 22, 21– 29 10.1097/WAD.0b013e3181611024 18317243 · DOI
  28. Grathwohl S. A. Kälin R. E. Bolmont T. Prokop S. Winkelmann G. Kaeser S. A. Odenthal J. Radde R. Eldh T. Gandy S. Aguzzi A. Staufenbiel M. Mathews P. M. Wolburg H. Heppner F. L. Jucker M. (2009). Formation and maintenance of Alzheimer's disease beta-amyloid plaques in the absence of microglia. Nat. Neurosci. 12, 1361– 1363 10.1038/nn.2432 19838177 PMC4721582 · DOI · Paper page
  29. Halliday G. M. Shepherd C. E. McCann H. Reid W. G. Grayson D. A. Broe G. A. Kril J. J. (2000). Effect of anti-inflammatory medications on neuropathological findings in Alzheimer disease. Arch. Neurol. 57, 831– 836 10.1001/archneur.57.6.831 10867780 · DOI · Paper page
  30. Hayden K. M. Zandi P. P. Khachaturian A. S. Szekely C. A. Fotuhi M. Norton M. C. Tschanz J. T. Pieper C. F. Corcoran C. Lyketsos C. G. Breitner J. C. Welsh-Bohmer K. A. (2007). Cache County Investigators. Does NSAID use modify cognitive trajectories in the elderly? The Cache County study. Neurology 69, 275– 282 10.1212/01.wnl.0000265223.25679.2a 17636065 · DOI
  31. Heneka M. T. Sastre M. Dumitrescu-Ozimek L. Hanke A. Dewachter I. Kuiperi C. O'Banion K. Klockgether T. Van Leuven F. Landreth G. E. (2005). Acute treatment with the PPARγ agonist pioglitazone and ibuprofen reduces glial inflammation and Aβ1-42 levels in APPV717I transgenic mice. Brain 128, 1442– 1453 10.1093/brain/awh452 15817521 · DOI · Paper page
  32. Hoozemans J. J. Rozemuller J. M. van Haastert E. S. Veerhuis R. Eikelenboom P. (2008). Cyclooxygenase-1 and -2 in the different stages of Alzheimer's disease pathology. Curr. Pharm. Des. 14, 1419– 1427 10.2174/138161208784480171 18537664 · DOI · Paper page
  33. Imbimbo B. P. (2004). The potential role of non-steroidal anti-inflammatory drugs in treating Alzheimer's disease. Expert Opin. Investig. Drugs 13, 1469– 1481 10.1517/13543784.13.11.1469 15500394 · DOI
  34. Imbimbo B. P. (2009). Why did tarenflurbil fail in Alzheimer's disease. J. Alzheimers Dis. 17, 757– 760 19542625
  35. Imbimbo B. P. Del Giudice E. Colavito D. D'Arrigo A. Dalle Carbonare M. Villetti G. Facchinetti F. Volta R. Pietrini V. Baroc M. F. Serneels L. De Strooper B. Leon A. (2007). CHF5074, a novel γ-secretase modulator, reduces brain β-amyloid pathology in a transgenic mouse model of Alzheimer's disease without causing peripheral toxicity. J. Pharmacol. Exp. Ther. 323, 822– 830 10.1124/jpet.107.129007 17895400 · DOI
  36. Iwata Y. Nicole O. Zurakowski D. Okamura T. Jonas R. A. Iwata Y. Nicole O. Zurakowski D. Okamura T. Jonas R. A. (2010). Ibuprofen for neuroprotection after cerebral ischemia. J. Thorac. Cardiovasc. Surg. 139, 489– 493 10.1016/j.jtcvs.2009.05.049 19853865 PMC2850810 · DOI
  37. Jin K. Peel A. L. Mao X. O. Xie L. Cottrell B. A. Henshall D. C. Greenberg D. A. (2004). Increased hippocampal neurogenesis in Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A. 101, 343– 347 10.1073/pnas.2634794100 14660786 PMC314187 · DOI · Paper page
  38. Khansari P. S. Halliwell R. F. (2009). Evidence for neuroprotection by the fenamate NSAID, mefenamic acid. Neurochem. Int. 55, 683– 688 10.1016/j.neuint.2009.06.014 19563851 · DOI
  39. Koenigsknecht-Talboo J. Landreth G. E. (2005). Microglial phagocytosis induced by fibrillar β-amyloid and IgGs are differentially regulated by proinflammatory cytokines. J. Neurosci. 25, 8240– 8249 10.1523/JNEUROSCI.1808-05.2005 16148231 PMC6725530 · DOI · Paper page
  40. Kotilinek L. A. Westerman M. A. Wang Q. Panizzon K. Lim G. P. Simonyi A. Lesne S. Falinska A. Younkin L. H. Younkin S. G. Rowan M. Cleary J. Wallis R. A. Sun G. Y. Cole G. Frautschy S. Anwyl R. Ashe K. H. (2008). Cyclooxygenase-2 inhibition improves amyloid-β-mediated suppression of memory and synaptic plasticity. Brain 131, 651– 664 10.1093/brain/awn008 18292081 PMC2628581 · DOI
  41. Kuchibhotla K. V. Lattarulo C. R. Hyman B. T. Bacskai B. J. (2009). Synchronous hyperactivity and intercellular calcium waves in astrocytes in Alzheimer mice. Science 323, 1211– 1215 10.1126/science.1169096 19251629 PMC2884172 · DOI · Paper page
  42. Kukar T. L. Ladd T. B. Bann M. A. Fraering P. C. Narlawar R. Maharvi G. M. Healy B. Chapman R. Welzel A. T. Price R. W. Moore B. Rangachari V. Cusack B. Eriksen J. Jansen-West K. Verbeeck C. Yager D. Eckman C. Ye W. Sagi S. Cottrell B. A. Torpey J. Rosenberry T. L. Fauq A. Wolfe M. S. Schmidt B. Walsh D. M. Koo E. H. Golde T. E. (2008). Substrate-targeting γ-secretase modulators. Nature 453, 925– 929 10.1038/nature07055 18548070 PMC2678541 · DOI
  43. Landi F. Cesari M. Onder G. Russo A. Torre S. Bernabei R. (2003). Non-steroidal anti-inflammatory drug (NSAID) use and Alzheimer disease in community-dwelling elderly patients. Am. J. Geriatr. Psychiatry 11, 179– 185 12611747
  44. Mackenzie I. R. Munoz D. G. (1998). Nonsteroidal anti-inflammatory drug use and Alzheimer-type pathology in aging. Neurology 50, 986– 990 9566383
  45. Maillard M. Burnier M. (2006). Comparative cardiovascular safety of traditional nonsteroidal anti-inflammatory drugs. Expert Opin. Drug. Saf. 5, 83– 94 10.1517/14740338.5.1.83 16370958 · DOI
  46. Malm T. M. Koistinaho M. Pa¨repalo M. Vatanen T. Ooka A. Karlsson S. Koistinaho J. (2005). Bone-marrow-derived cells contribute to the recruitment of microglial cells in response to β-amyloid deposition in APP/PS1 double transgenic Alzheimer mice. Neurobiol. Dis. 18, 134– 142 10.1016/j.nbd.2004.09.009 15649704 · DOI · Paper page
  47. Mandrekar S. Jiang Q. Lee C. Y. Koenigsknecht-Talboo J. Holtzman D. M. Landreth G. E. (2009). Microglia mediate the clearance of soluble Abeta through fluid phase macropinocytosis. J. Neurosci. 29, 4252– 4262 10.1523/JNEUROSCI.5572-08.2009 19339619 PMC3034143 · DOI · Paper page
  48. Masters C. L. Wyss-Coray T. Giulio Pasinetti G. M. (2008). Anti-inflammatory drugs fall short in Alzheimer's disease. Nat. Med. 14, 916 10.1038/nm0908-916 18776882 · DOI
  49. McGettigan P. Henry D. (2006). Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 296, 1633– 1644 10.1001/jama.296.13.jrv60011 16968831 · DOI
  50. McShea A. Harris P. L. Webster K. R. Wahl A. F. Smith M. A. (1997). Abnormal expression of the cell cycle regulators P16 and CDK4 in Alzheimer's disease. Am. J. Pathol. 150, 1933– 1939 9176387 PMC1858317
  51. Morihara T. Teter B. Yang F. Lim G. P. Boudinot S. Boudinot F. D. Frautschy S. A. Cole G. M. (2005). Ibuprofen suppresses interleukin-1β induction of pro-amyloidogenic α1-antichymotrypsin to ameliorate β-amyloid (Aβ) pathology in Alzheimer's models. Neuropsychopharmacology 30, 1111– 1120 10.1038/sj.npp.1300668 15688088 · DOI
  52. Nilsson L. N. Arendash G. W. Leighty R. E. Costa D. A. Low M. A. Garcia M. F. Cracciolo J. R. Rojiani A. Wu X. Bales K. R. Paul S. M. Potter H. (2004). Cognitive impairment in PDAPP mice depends on ApoE and ACT-catalyzed amyloid formation. Neurobiol. Aging 25, 1153– 1167 10.1016/j.neurobiolaging.2003.12.011 15312961 · DOI
  53. Olah M. Ping G. De Haas A. H. Brouwer N. Meerlo P. Van Der Zee E. A. Biber K. Boddeke H. W. (2009). Enhanced hippocampal neurogenesis in the absence of microglia T cell interaction and microglia activation in the murine running wheel model. Glia 57, 1046– 1061 10.1002/glia.20828 19115394 · DOI
  54. Opar A. (2008). Mixed results for disease-modification strategies for Alzheimer's disease. Nat. Rev. Drug Discov. 7, 717– 718 10.1038/nrd2676 19172684 · DOI
  55. Reines S. A. Block G. A. Morris J. C. Liu G. Nessly M. L. Lines C. R. Norman B. A. Baranak C. C. (2004). Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study. Neurology 62, 66– 71 14718699
  56. Richardson R. L. Kim E. M. Shephard R. A. Gardiner T. Cleary J. O'Hare E. (2002). Behavioural and histopathological analyses of ibuprofen treatment on the effect of aggregated Aβ1-42 injections in the rat. Brain Res. 954, 1– 10 10.1016/S0006-8993(02)03006-8 12393227 · DOI
  57. Rogers J. Kirby L. C. Hempelman S. R. Berry D. L. Mcgeer P. L. Kaszniak A. W. Zalinski J. Cofield M. Mansukhani L. Willson P. Kogan F. (1993). Clinical trial of indomethacin in Alzheimer's disease. Neurology 43, 1609– 1611 8351023
  58. Sainati S. M. Ingram D. M. Talwalker S. Geis G. (2000). “ Results of a double-blind, randomized, placebo-controlled study of celecoxib in the treatment of progression of Alzheimer's disease,” in 6th International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy (Stockholm, Sweden) April 5–8, Abstract Book (p. 180).
  59. Sanz-Blasco S. Valero R. A. Rodríguez-Crespo I. Villalobos C. Núñez L. (2008). Mitochondrial Ca2+ overload underlies Aβ oligomers neurotoxicity providing an unexpected mechanism of neuroprotection by NSAIDs. PLoS ONE 3: e2718 10.1371/journal.pone.0002718 18648507 PMC2447871 · DOI
  60. Sasaki T. Kitagawa K. Sugiura S. Omura-Matsuoka E. Tanaka S. Yagita Y. Okano H. Matsumoto M. Hori M. (2003). Implication of cyclooxygenase-2 on enhanced proliferation of neural progenitor cells in the adult mouse hippocampus after ischemia. J. Neurosci. Res. 72, 461– 471 10.1002/jnr.10595 12704808 · DOI
  61. Sastre M. Dewachter I. Landreth G. E. Willson T. M. Klockgether T. Van Leuven F. Heneka M. T. (2003). Nonsteroidal anti-inflammatory drugs and peroxisome proliferator-activated receptor-γ agonists modulate immunostimulated processing of amyloid precursor protein through regulation of β-secretase. J. Neurosci. 23, 9796– 9804 14586007 PMC6740896
  62. Sastre M. Dewachter I. Rossner S. Bogdanovic N. Rosen E. Borghgraef P. Evert B. O. Dumitrescu-Ozimek L. Thal D. R. Landreth G. Walter J. Klockgether T. van Leuven F. Heneka M. T. (2006). Nonsteroidal anti-inflammatory drugs repress β-secretase gene promoter activity by the activation of PPARγ. Proc. Natl. Acad. Sci. U.S.A. 103, 443– 448 10.1073/pnas.0503839103 16407166 PMC1326151 · DOI · Paper page
  63. Scharf S. Mander A. Ugoni A. Vajda F. Christophidis N. P. (1999). A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease. Neurology 53, 197– 201 10408559
  64. Shors T. J. Miesegaes G. Beylin A. Zhao M. Rydel T. Gould E. (2001). Neurogenesis in the adult is involved in the formation of trace memories. Nature 410, 372– 376 10.1038/35066584 11268214 · DOI
  65. Simard A. R. Soulet D. Gowing G. Julien J. P. Rivest S. (2006). Bone marrow derived microglia play a critical role in restricting senile plaque formation in Alzheimer's disease. Neuron 49, 489– 502 10.1016/j.neuron.2006.01.022 16476660 · DOI · Paper page
  66. Small G. W. Siddarth P. Silverman D. H. Ercoli L. M. Miller K. J. Lavretsky H. Bookheimer S. Y. Huang S. C. Barrio J. R. Phelps M. E. (2008). Cognitive and cerebral metabolic effects of celecoxib versus placebo in people with age-related memory loss: randomized controlled study. Am. J. Geriatr. Psychiatry 16, 999– 1009 10.1097/JGP.0b013e31818cd3a4 19038899 PMC2693408 · DOI
  67. Small S. A. Duff K. (2008). Linking Aβ and tau in late-onset alzheimer's disease: a dual pathway hypothesis. Neuron 60, 534– 542 10.1016/j.neuron.2008.11.007 19038212 PMC2692134 · DOI · Paper page
  68. Soininen H. West C. Robbins J. Niculescu L. (2007). Long-term efficacy and safety of celecoxib in Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 23, 8– 21 10.1159/000096588 17068392 · DOI
  69. Stéphan A. Laroche S. Davis S. (2003). Learning deficits and dysfunctional synaptic plasticity induced by aggregated amyloid deposits in the dentate gyrus are rescued by chronic treatment with indomethacin. Eur. J. Neurosci. 17, 1921– 1927 10.1046/j.1460-9568.2003.02610.x 12752791 · DOI
  70. Sung S. Yang H. Uryu K. Lee E. B. Zhao L. Shineman D. Trojanowski J. Q. Lee V. M. Praticò D. (2004). Modulation of NF-κB activity by indomethacin influences Aβ levels but not APP metabolism in a model of Alzheimer disease. Am. J. Pathol. 165, 2197– 2206 15579461 PMC1618710
  71. Szekely C. A. Breitner J. C. Fitzpatrick A. L. Rea T. D. Psaty B. M. Kuller L. H. Zandi P. P. (2008a). NSAID use and dementia risk in the Cardiovascular Health Study: role of APOE and NSAID type. Neurology 70, 17– 24 10.1212/01.wnl.0000284596.95156.48 18003940 PMC2877629 · DOI · Paper page
  72. Szekely C. A. Thorne J. E. Zandi P. P. Ek M. Messias E. Breitner J. C. Goodman S. N. (2004). Nonsteroidal anti-inflammatory drugs for the prevention of Alzheimer's disease: a systematic review. Neuroepidemiology 23, 159– 169 10.1159/000078501 15279021 · DOI
  73. Thomas T. Nadackal T. G. Thomas K. (2001). Aspirin and non-steroidal anti-inflammatory drugs inhibit amyloid-β aggregation. Neuroreport 12, 3263– 3267 10.1097/00001756-200110290-00024 11711868 · DOI
  74. Van Gool W. A. Weinstein H. C. Scheltens P. Walstra G. J. Scheltens P. K. (2001). Effect of hydroxychloroquine on progression of dementia in early Alzheimer's disease: an 18 month randomised, double-blind, placebo-controlled study. Lancet 358, 455– 460 10.1016/S0140-6736(01)05623-9 11513909 · DOI
  75. Varvel N. H. Bhaskar K. Kounnas M. Z. Wagner S. L. Yang Y. Lamb B. T. Herrup K. (2009). NSAIDs prevent, but do not reverse, neuronal cell cycle reentry in a mouse model of Alzheimer disease. J. Clin. Invest. 119, 3692– 3702 19907078 PMC2786797
  76. Weggen S. Czirr E. Leuchtenberger S. Eriksen J. (2007). “ Nonsteroidal anti-inflammatory drugs (NSAIDs) and derived Aβ42-lowering molecules for treatment and prevention of Alzheimer's disease (AD),” in Pharmacological Mechanisms in Alzheimer's Therapeutics, ed. Cuello C. A. (New York: Springer), 167– 193
  77. Wilcock G. K. Black S. E. Hendrix S. B. Zavitz K. H. Swabb E. A. Laughlin M. A. (2008). Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial. Lancet Neurol. 7, 483– 493 10.1016/S1474-4422(08)70090-5 18450517 · DOI
  78. Wyss-Coray T. (2006). Inflammation in Alzheimer disease: driving force, bystander or beneficial response? Nat. Med. 12, 1005– 1015 16960575
  79. Yang Y. Geldmacher D. S. Herrup K. (2001). DNA replication precedes neuronal cell death in Alzheimer's disease. J. Neurosci. 21, 2661– 2668 11306619 PMC6762514
  80. Yip A. G. Green R. C. Huyck M. Cupples L. A. Farrer L. A. (2005). MIRAGE Study Group. Nonsteroidal anti-inflammatory drug use and Alzheimer's disease risk: the MIRAGE Study. BMC Geriatr. 5, 2 10.1186/1471-2318-5-2 15647106 PMC546007 · DOI
  81. Zandi P. P. Anthony J. C. Hayden K. M. Mehta K. Mayer L. Breitner J. C. (2002). Reduced incidence of AD with NSAID but not H2 receptor antagonists: the Cache County Study. Neurology 59, 880– 886 12297571
  82. Zhao L. Lin S. Bales K. R. Gelfanova V. Koger D. Delong C. Hale J. Liu F. Hunter J. M. Paul S. M. (2009). Macrophage-mediated degradation of β-amyloid via an apolipoprotein E isoform-dependent mechanism. J. Neurosci. 29, 3603– 3612 10.1523/JNEUROSCI.5302-08.2009 19295164 PMC6665249 · DOI
  83. Zhao X. Rebeck G. W. Hoe H. S. Andrews P. M. (2008). Tarenflurbil protection from cytotoxicity is associated with an upregulation of neurotrophins. J. Alzheimers Dis. 15, 397– 407 18997293

Cited by

Sorted by citations

Metadata

Authors
Imbimbo
Venue
Frontiers in Aging Neuroscience
Publisher
Frontiers Media SA
Published
2010
ISSN
1663-4365
DOI
10.3389/fnagi.2010.00019
PMC
PMC2912027
Cited by
75
References
21

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review